AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18845008 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy (CBT)
Number of subjects: 93
Study 16671972 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention using the 'Drink‐Less' protocol
Number of subjects: 127
Study 16671972 — intervention group
Group type: COMPARATOR
Intervention: Standard advice (control condition)
Number of subjects: 127
Study 15293581 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous morphine and procedural information
Number of subjects: 74
Study 15293581 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intravenous ketorolac and procedural information
Number of subjects: 74
Study 15293581 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous morphine plus procedural and sensory information
Number of subjects: 74
Study 15293581 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg intravenous ketorolac plus procedural and sensory information
Number of subjects: 74
Study 15293581 — intervention group
Group type: COMPARATOR
Intervention: All interventions (morphine and ketorolac)
Number of subjects: 74
Study 11743502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic transfusion
Number of subjects: 130
Study 11743502 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 130
Study 9417009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring block
Number of subjects: 52
Study 9417009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block
Number of subjects: 52
Study 9417009 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EMLA
Number of subjects: 52
Study 9417009 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo (no anesthetic)
Number of subjects: 52
Study 7619991 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A) - no additional interventions
Number of subjects: 180
Study 7619991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of fluconazole (group B)
Number of subjects: 180
Study 7619991 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous administration of amphotericin B (group C)
Number of subjects: 180
Study 7619991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bladder irrigation with amphotericin B at low concentration (group D)
Number of subjects: 180
Study 7619991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bladder irrigation with amphotericin B at medium concentration (group E)
Number of subjects: 180
Study 7619991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bladder irrigation with amphotericin B at high concentration (group F)
Number of subjects: 180
Study 2571625 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma desensitization, hypnotherapy, and psychodynamic therapy
Number of subjects: 112
Study 2571625 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 112
Study 346292 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 13
Study 346292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 346292 — intervention group
Group type: COMPARATOR
Intervention: Aspirin or Placebo
Number of subjects: 13
Study 30608623 — intervention group
Group type: EXPERIMENTAL
Intervention: LARC FIRST video contraceptive counseling along with routine prenatal care
Number of subjects: 67
Study 30608623 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care alone
Number of subjects: 67
Study 28646812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation (300 mg/d for weeks 1-4, 150 mg/d for weeks 5-8)
Number of subjects: 26
Study 28646812 — intervention group
Group type: COMPARATOR
Intervention: Control group (rice flour placebo, similar dosing to intervention group)
Number of subjects: 26
Study 28646812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation
Number of subjects: 26
Study 27099132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (SIDIAP)
Number of subjects: 35537
Study 27099132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (DHR)
Number of subjects: 35537
Study 23358230 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Cigarette
Number of subjects: 14
Study 20888728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular prevention program (n=208)
Number of subjects: 314
Study 20888728 — intervention group
Group type: COMPARATOR
Intervention: Usual care (medical assessment) (n=106)
Number of subjects: 314
Study 19960132 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support (n=45)
Number of subjects: 95
Study 19960132 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=50)
Number of subjects: 95
Study 17118704 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up only
Number of subjects: 14
Study 17118704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching only
Number of subjects: 14
Study 17118704 — intervention group
Group type: COMPARATOR
Intervention: No preparation
Number of subjects: 14
Study 17118704 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up and stretching
Number of subjects: 14
Study 14697682 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles
Number of subjects: 156
Study 14697682 — intervention group
Group type: COMPARATOR
Intervention: Neutrally wedged insoles (Control)
Number of subjects: 156
Study 11303598 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine/oltipraz (NAC/OLZ) combination, OLZ 200 mg (Arm B)
Number of subjects: 19
Study 11303598 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine/oltipraz (NAC/OLZ) combination, OLZ 400 mg (Arm C)
Number of subjects: 19
Study 11303598 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine/oltipraz (NAC/OLZ) combination, placebo (Arm A)
Number of subjects: 19
Study 11303598 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine/oltipraz (NAC/OLZ) combination
Number of subjects: 19
Study 8884875 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (800 mg orally four times daily)
Number of subjects: 12
Study 8884875 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (280 mg orally twice daily)
Number of subjects: 12
Study 8884875 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate with clodronate
Number of subjects: 12
Study 8884875 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate with estramustine phosphate
Number of subjects: 12
Study 1669598 — intervention group
Group type: EXPERIMENTAL
Intervention: Local immunotherapy (LI) by inhalation of a powder extract of house dust mite (HDM)
Number of subjects: 10
Study 1669598 — intervention group
Group type: COMPARATOR
Intervention: Parenteral immunotherapy (PI) by injection
Number of subjects: 10
Study 6601670 — intervention group
Group type: EXPERIMENTAL
Intervention: SRW intranasal immunotherapy (n = 11); cumulative AgE doses from 3 to 59 micrograms (mean 21)
Number of subjects: 20
Study 6601670 — intervention group
Group type: COMPARATOR
Intervention: OG control (n = 9)
Number of subjects: 20
Study 30840130 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban therapy (Group 1, n=32)
Number of subjects: 97
Study 30840130 — intervention group
Group type: COMPARATOR
Intervention: Interrupted apixaban therapy (Group 2, n=65)
Number of subjects: 97
Study 30840130 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 97
Study 29235300 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine and Western medicine treatment (Buxin Yishen decoction)
Number of subjects: 0
Study 29235300 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine treatment (control group)
Number of subjects: 0
Study 27647057 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisession telephone counseling from study staff (n=804)
Number of subjects: 1618
Study 27647057 — intervention group
Group type: COMPARATOR
Intervention: Referral to the state quitline for proactive outreach and counseling (n=814)
Number of subjects: 1618
Study 24435207 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (8 mg/day for 6 months)
Number of subjects: 105
Study 24435207 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 105
Study 24435207 — intervention group
Group type: COMPARATOR
Intervention: Control (no silodosin)
Number of subjects: 105
Study 23057616 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention (educational video and handbook)
Number of subjects: 0
Study 23057616 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention plus financial assistance program
Number of subjects: 0
Study 23057616 — intervention group
Group type: COMPARATOR
Intervention: Usual dialysis care
Number of subjects: 0
Study 19079954 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment combined with cognitive-behavioral therapy (CBT)
Number of subjects: 130
Study 19079954 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (3 months)
Number of subjects: 130
Study 17846890 — intervention group
Group type: EXPERIMENTAL
Intervention: Group HIV prevention intervention
Number of subjects: 0
Study 17846890 — intervention group
Group type: COMPARATOR
Intervention: Control, career exploration condition
Number of subjects: 0
Study 15357013 — intervention group
Group type: EXPERIMENTAL
Intervention: Würzburg training program of phonological awareness
Number of subjects: 80
Study 15357013 — intervention group
Group type: COMPARATOR
Intervention: Regular kindergarten program (Control)
Number of subjects: 80
Study 11719017 — intervention group
Group type: EXPERIMENTAL
Intervention: Eudragit L 30 D‐55 coated capsules
Number of subjects: 0
Study 11719017 — intervention group
Group type: EXPERIMENTAL
Intervention: Eudragit FS 30 D coated capsules
Number of subjects: 0
Study 9620358 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD3 monoclonal antibody (mAb) OKT3 and phorbol myristate acetate (PMA) stimulation in young humans
Number of subjects: 0
Study 9620358 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD3 monoclonal antibody (mAb) OKT3 and phorbol myristate acetate (PMA) stimulation in elderly humans
Number of subjects: 0
Study 9620358 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD3/PMA stimulation in elderly humans
Number of subjects: 0
Study 9620358 — intervention group
Group type: COMPARATOR
Intervention: Resting T cells from young humans
Number of subjects: 0
Study 9620358 — intervention group
Group type: COMPARATOR
Intervention: Resting T cells from elderly humans
Number of subjects: 0
Study 9620358 — intervention group
Group type: COMPARATOR
Intervention: Resting and stimulated T cells
Number of subjects: 0
Study 7616847 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous Intralipid infusion (test 1)
Number of subjects: 6
Study 7616847 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (30 U/min) plus low-dose Intralipid infusion (test 2)
Number of subjects: 6
Study 7616847 — intervention group
Group type: COMPARATOR
Intervention: Control study (test 3)
Number of subjects: 6
Study 1969013 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion
Number of subjects: 97
Study 1969013 — intervention group
Group type: COMPARATOR
Intervention: Heparin bolus
Number of subjects: 97
Study 1969013 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 97
Study 1969013 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 97
Study 6448885 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Deprenil plus L-5-HTP and benzerazide
Number of subjects: 18
Study 6448885 — intervention group
Group type: COMPARATOR
Intervention: L-5-HTP and benzerazide
Number of subjects: 18
Study 6448885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30810061 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EXT) - 3 × 45 min of supervised exercise per week at 60‐85% heart rate reserve for 12 weeks
Number of subjects: 36
Study 30810061 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EXT)
Number of subjects: 36
Study 30810061 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - routine care
Number of subjects: 36
Study 30810061 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study 29081098 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl glutamine injection plus conventional therapy
Number of subjects: 80
Study 29081098 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 80
Study 26480877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 2 g by topical application
Number of subjects: 111
Study 26480877 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 111
Study 23596780 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaochaihu Decoction (XD)
Number of subjects: 70
Study 23596780 — intervention group
Group type: COMPARATOR
Intervention: Shenyan Kangfu Tablet (SKT)
Number of subjects: 70
Study 21321793 — intervention group
Group type: EXPERIMENTAL
Intervention: Filipino Americans
Number of subjects: 20712
Study 21321793 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean Americans
Number of subjects: 20712
Study 21321793 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese Americans
Number of subjects: 20712
Study 21321793 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic whites
Number of subjects: 20712
Study 19180358 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose
Number of subjects: 21
Study 19180358 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose/Fructose combination
Number of subjects: 21
Study 19180358 — intervention group
Group type: COMPARATOR
Intervention: Glucose control
Number of subjects: 21
Study 17192336 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide 1.5 mg/day (divided into four subcutaneous doses) for 6 months
Number of subjects: 139
Study 17192336 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide 4.5 mg/day for 6 months
Number of subjects: 139
Study 17192336 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide treatment
Number of subjects: 139
Study 17192336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 15232043 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 28
Study 15232043 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 28
Study 11578284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hernioplasty (polypropylene mesh or plug)
Number of subjects: 200
Study 11578284 — intervention group
Group type: COMPARATOR
Intervention: Herniorrhaphy (primary suture)
Number of subjects: 200
Study 9462481 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive listening
Number of subjects: 9
Study 9462481 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple reaction task
Number of subjects: 9
Study 9462481 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice-reaction task (target probability = 0.5)
Number of subjects: 9
Study 9462481 — intervention group
Group type: EXPERIMENTAL
Intervention: Early auditory gamma band responses
Number of subjects: 9
Study 9462481 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gamma responses
Number of subjects: 9
Study 7945477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg/kg/day)
Number of subjects: 122
Study 3115044 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 8
Study 3115044 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg/kg
Number of subjects: 8
Study 3115044 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.5 mg/kg
Number of subjects: 8
Study 3115044 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.4 mg
Number of subjects: 8
Study 29723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction in SLE patients with lower education (9 years) compared to normal cognitive function (12 years), P = 0.006
Number of subjects: 100
Study 29723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction in SLE patients with higher body mass index (26.7) compared to normal cognitive function (24.3), P = 0.03
Number of subjects: 100
Study 29723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction in SLE patients with positive IgG anticardiolipin antibodies (50%) compared to normal cognitive function (18%), P = 0.009
Number of subjects: 100
Study 29723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction in SLE patients with a higher median number of concomitant NPSLE syndromes (3) compared to normal cognitive function (1), P = 0.04
Number of subjects: 100
Study 29723220 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL2 levels in CSF of SLE patients with cognitive dysfunction [886.1 (374.9–1439.7) pg/mL] compared to normal cognitive function [515.8 (3.2–1958.2) pg/mL], P = 0.04
Number of subjects: 100
Study 28870217 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (10 mg) administered daily from early follicular phase
Number of subjects: 204
Study 28870217 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle IVF
Number of subjects: 204
Study 26216383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg i.v. q4 weeks during the first three cycles of carboplatin (AUC5) plus doxorubicin (PLD 30 mg/m2 or doxorubicin 50 mg/m2 i.v., day 1, q4 weeks, for six cycles)
Number of subjects: 23
Study 26216383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg i.v. q4 weeks
Number of subjects: 23
Study 22218118 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan, 25 mg, twice per day
Number of subjects: 70
Study 22218118 — intervention group
Group type: COMPARATOR
Intervention: Losartan + N-acetyl cysteine (NAC), 600 mg twice daily
Number of subjects: 70
Study 21137665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hr anesthesia duration
Number of subjects: 60
Study 21137665 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hr anesthesia duration
Number of subjects: 60
Study 21137665 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hr anesthesia duration
Number of subjects: 60
Study 16334146 — intervention group
Group type: EXPERIMENTAL
Intervention: Isorel
Number of subjects: 70
Study 16334146 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 11927210 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with a positive outcome (statistically significant)
Number of subjects: 530
Study 9579008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to screen for colorectal cancer
Number of subjects: 2693
Study 9579008 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with intention to screen
Number of subjects: 2693
Study 7806416 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate dialysis (AD)
Number of subjects: 15
Study 7806416 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis (BD)
Number of subjects: 15
Study 7806416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate hemofiltration (LHF)
Number of subjects: 15
Study 7806416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 15
Study 2698748 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizoate
Number of subjects: 32
Study 2698748 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 32
Study 2698748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Metrizoate and Iohexol
Number of subjects: 32
Study 964138 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (Kopenhagen strain) at 160.000 organisms per dose
Number of subjects: 217
Study 964138 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine (Kopenhagen strain) at lower concentrations (22.000, 50.000, 110.000 organisms per dose)
Number of subjects: 217
Study 30866056 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus bendamustine
Number of subjects: 0
Study 30866056 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus CHOP/CVP
Number of subjects: 0
Study 29468715 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9977 (5 to 1200 mg)
Number of subjects: 23
Study 29468715 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9977/eplerenone combination
Number of subjects: 23
Study 29468715 — intervention group
Group type: COMPARATOR
Intervention: Fludrocortisone alone
Number of subjects: 23
Study 29468715 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 23
Study 26827266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide therapy
Number of subjects: 54
Study 24757219 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV-naive
Number of subjects: 500
Study 24757219 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV-experienced
Number of subjects: 500
Study 24757219 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 500
Study 22910755 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents with biodegradable polymer
Number of subjects: 1161
Study 22910755 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1161
Study 20357504 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa seed supplementation (2 g/day orally) for 30 days
Number of subjects: 24
Study 20357504 — intervention group
Group type: COMPARATOR
Intervention: Specific immunotherapy
Number of subjects: 24
Study 20357504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1 ml saline solution subcutaneously once a week)
Number of subjects: 24
Study 17234726 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 17234726 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 17234726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17234726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypurinol
Number of subjects: 0
Study 16146597 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart under mild hypothermia and CPB
Number of subjects: 40
Study 16146597 — intervention group
Group type: COMPARATOR
Intervention: Heart arrest by using cold blood cardioplegia and CPB
Number of subjects: 40
Study 12151429 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH 150 IU only
Number of subjects: 120
Study 12151429 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH 150 IU and LH activity 37.5 IU
Number of subjects: 120